History Back
2011
06-22
GEM IPO Application for Shanxi C&Y Approved by CSRC - Grandall Shanghai Office Acted as Issuer's Counsel
June 22, 2011 - Shanghai, China - The application for the IPO of C&Y Pharmaceutical Investment Holdings Ltd. (“Shanxi C&Y”) on GEM has been passed and approved on the 37th meeting of the Securities Public Offering Examination and Approval Committee for GEM of China Securities Regulatory Commission (“CSRC”) on June 21, 2011.
Shanxi C&Y is a Pharmaceutical enterprise focusing on research & development, production and sale of anti-infection drugs and has been highly recognized as a high-tech enterprise by various departments and agencies, such as Shanxi Science and Technology Department, Shanxi Finance Bureau, Shanxi Provincial Office and Shanxi Local Taxation Bureau. The company, with competent strength in the fields of new penicillin, is engaged in the production of anti-infection drugs and other pharmaceutical products.
Shanxi C&Y proposes to offer 33,800,000 shares, primarily for the purposes of investment in construction of relevant production lines and plants.
Grandall Shanghai Office has been retained as the Issuer’s Counsel. Mr. Yao Yi, Mr. Du Tong and Mr. Zhang Yu are the key Grandall attorneys servicing Shanxi C&Y.
Click here to see more: C&Y Pharmaceutical Investment Holdings Ltd.